DRESDEN, Germany, 20 June, 2023 – denovoMATRIX GmbH, an innovator in cell and gene therapy manufacturing, and Saint-Gobain Life Sciences have expanded their Master Service Agreement with a special focus on products related to the Stem Cell therapy market. At the same time, Saint-Gobain Life Sciences’ investment arm NOVA announces its strategic investment into denovoMATRIX. [Read more…]
Celularity – Big Bucks, Billionaire Investors, Bold Dreams
Celularity is a biotechnology company that specializes in leveraging biologically active cell populations within the postpartum human placenta. Founded on the pioneering work of Robert Hariri, MD, PhD, in human placenta-derived cellular therapeutics and biomaterials, Celularity is uniquely positioned to harness the potential of most biocreative event on earth: human birth. [Read more…]
Neobiosis Announces FDA Approval of IND for Use of ViXomeTM in COVID-19 ‘Post Covid Syndrome’
GAINESVILLE, Fla., – Neobiosis, is a leading research and manufacturing biotechnology company focused on pioneering the development of novel therapeutics from perinatal tissues as a new class of medicines. Today, Neobiosis announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for ViXome™, its drug for the treatment of ‘Post COVID Syndrome (AKA “Long Haul COVID Syndrome”). [Read more…]
StemInov Will Bioproduct the First Cell Therapy Drug to Treat Inflammatory Diseases
NANCY-STRASBOURG, France –StemInov, a biotechnology company developing an innovative biomedicine based on stem cells from umbilical cords to treat inflammatory diseases, septic shock and acute respiratory distress syndrome (ARDS), will bioproduct the first cell therapy drug from umbilical cord stem. In this context, StemInov’s promising disruptive innovations has been selected to join the French Tech – Health20 program launched by the French Government that will accelerate the development of StemInov’s proprietary and collaborative programs with greater visibility in France and internationally. [Read more…]
Dr. Chris Centeno, Visionary Behind Regenexx® Stem Cell Technology
Dr. Chris Centeno is an international expert in regenerative medicine and the clinical use of mesenchymal stem cells (MSCs) for orthopedic applications. This is Part 2 of an interview with Dr. Centeno.
Read Part 1 of the interview here.
ACL Surgeries and Regenexx Stem Cell Technology
Dr. Centeno specializes in clinical use of adult stem cells for orthopedic injuries, which he treats through same-day procedures at his clinic in Denver, Colorado, and through cultured expansion of mesenchymal stem cells at a clinic in Grand Cayman. He first performed these adult stem cell procedures in the U.S. in 2005-2006, and his clinic has since has treated thousands orthopedic patients with stem cell based therapies.
Dr. Chris Centeno is best known for the Regenexx® technology, an approach that uses needle-based procedures coupled with sophisticated guidance techniques to place large numbers of stem cells at the site needing repair. This approach can often replace the need for invasive orthopedic surgeries. [Read more…]
- « Previous Page
- 1
- …
- 122
- 123
- 124
- 125
- 126
- …
- 338
- Next Page »